NICE conditionally backs Vimizim, rebuffs Otezla

The U.K.'s NICE issued draft guidance conditionally recommending Vimizim elosulfase alfa from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to treat mucopolysaccharidosis IVA (MPS IVA; Morquio's syndrome), and issued final guidance recommending against use of Otezla apremilast from Celgene Corp. (NASDAQ:CELG) to treat chronic plaque psoriasis.

NICE required that BioMarin develop a protocol outlining clinical criteria for starting and stopping treatment with Vimizim, collaborate with patient organizations and NHS England to collect real-world data on the drug's use, and continue to support the MPS IVa registry. ...